Citations

Clear

1446 citation(s) found for "Howard, F".

Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)
Lenz, Heinz‐Josef , Höchster, Howard S. , Niedzwiecki, Donna , Goldberg, Richard M. , Blanke, Charles D. , Qu, Xueping , Wirapati, Pratyaksha , Innocenti, Federico , Kabbarah, Omar , Niedzwiecki, Donna , Ou, Fang‐Shu , Venook, Alan P. , Mayer, Robert J. , Bertagnolli, Monica M. , Zemla, Tyler , Tejpar, Sabine

Mayo Clinic

Journal of Clinical Oncology | May 1, 2019 | Volume: 37 | Issue: 22 | Pages: 1876-1885

10.1200/jco.18.02258 | PMID 31042420 Get It

PURPOSETo determine the predictive and prognostic value of the consensus molecular subtypes (CMSs) of colorectal cancer (CRC) that represent a merging of gene expression–based features largely in primary tumors from six independent classification systems and provide a framework for capturing the intrinsic heterogeneity of CRC in patients enrolled in CALGB/SWOG 80405.PATIENTS AND METHODSCALGB/SWOG 80405 is a phase III trial that compared the addition of bevacizumab or cetuximab to infusional fluorouracil, leucovorin, and oxaliplatin or fluorouracil, leucovorin, and irinotecan as first-line treatment of advanced CRC. We characterized the CMS classification using a novel NanoString gene expression panel on primary CRCs from 581 patients enrolled in this study to assess the prognostic and predictive value of CMSs in these patients.RESULTSThe CMSs are highly prognostic for overall survival (OS; P < .001) and progression-free survival (PFS; P < .001). Furthermore, CMSs were predictive for both OS ( P for interaction < .001) and PFS ( P for interaction = .0032). In the CMS1 cohort, patients treated with bevacizumab had a significantly longer OS than those treated with cetuximab ( P < .001). In the CMS2 cohort, patients treated with cetuximab had a significantly longer OS than patients treated with bevacizumab ( P = .0046).CONCLUSIONThese findings highlight the possible clinical utility of CMSs and suggests that refinement of the CMS classification may provide a path toward identifying patients with metastatic CRC who are most likely to benefit from specific targeted therapy as part of the initial treatment.
MyPathway: An open-label phase IIa study of trastuzumab/pertuzumab, erlotinib, vemurafenib, and vismodegib in patients who have advanced solid tumors with mutations or gene expression abnormalities targeted by these agents.
Burris, Howard A. , Hurwitz, Herbert I. , Perez, Edith A. , Hainsworth, John D. , Leon, Larry, Beattie, Mary, Brammer, Melissa, Spigel, David R. , Swanton, Charles , Leon, Larry, Sweeney, Christopher J.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS11111-TPS11111

10.1200/jco.2015.33.15_suppl.tps11111 Get It

Twin randomized studies of daratumumab (DARA; D) plus standard of care (lenalidomide/dexamethasone or bortezomib/dexamethasone [DRd or DVd]) versus Rd or Vd alone in relapsed or refractory multiple myeloma (MM): 54767414MMY3003 (Pollux) and 54767414MMY3004
Palumbo, Antonio , Reece, Donna , Sonneveld, Pieter , Spencer, Andrew , Chanan‐Khan, Asher , Goldschmidt, Hartmut , Yeh, Howard, Schecter, Jordan M. , Qin, Xiang , Amin, Himal, Guckert, Mary, Ahmadi, Tahamtan , Dimopoulos, Meletios Α. , Orlowski, Robert Z.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: TPS8609-TPS8609

10.1200/jco.2015.33.15_suppl.tps8609 Get It

American Joint Committee on Cancer eighth edition human papilloma virus positive oropharyngeal cancer staging system: Discordance between clinical and pathological staging systems
Hall, S. , Neel, Gregory S., Howard, Brittany E. , Nagel, Thomas H. , Hayden, Richard E. , Hinni, Michael L., Hall, Scott R , Chang, Brent A. , Lott, David G. , Zhang, Nan

Mayo Clinic

Head & Neck | April 2, 2019 | Volume: 41 | Issue: 8 | Pages: 2716-2723

10.1002/hed.25749 | PMID 30939209 Get It

AbstractBackgroundThe American Joint Committee on Cancer (AJCC) eighth edition introduces a staging system specific for human papilloma virus positive oropharyngeal cancer with separate clinical (AJCC 8c) and pathological (AJCC 8p) criteria.MethodsIn this retrospective cohort study, preoperative imaging and pathology reports were used to stage patients based on the AJCC 8c and AJCC 8p criteria, respectively. The primary endpoint was agreement between AJCC 8c and AJCC 8p.ResultsA total of 213 patients met inclusion criteria. Kappa statistics showed poor agreement (κ = 0.3275) between AJCC 8c and AJCC 8p. In total, 30.3% of patient's preoperative AJCC 8c stage changed based on the postoperative pathologic staging (AJCC 8p) with 73.4% of those being upstaged.ConclusionThese data suggest that disagreement exists between AJCC 8c and AJCC 8p, in part due to the separate clinical and pathological staging criteria. This discrepancy should be considered as the new system is implemented.
The Kronos Early Estrogen Prevention Study (KEEPS): what have we learned?
Miller, Virginia M. , Naftolin, Frederick , Asthana, Sanjay , Black, Dennis M. , Budoff, Matthew J. , Cedars, Marcelle I. , Dowling, N. Maritza , Gleason, Carey E. , Hodis, Howard N., Jayachandran, Muthuvel , Kantarci, Kejal , Løbo, Rogerio A. , Pal, Lubna , Taylor, Hugh S. , Harman, S. Mitchell , Asthana, Sanjay , Kantarci, Kejal , Budoff, Matthew , Brinton, Eliot A. , Manson, JoAnn E. , Santoro, Nanette F.

Mayo Clinic

Menopause | April 2, 2019 | Volume: 26 | Issue: 9 | Pages: 1071-1084

10.1097/gme.0000000000001326 | PMID 31453973 Get It

Abstract Objective: The Kronos Early Estrogen Prevention Study (KEEPS) was designed to address gaps in understanding the effects of timely menopausal hormone treatments (HT) on cardiovascular health and other effects of menopause after the premature termination of the Women's Health Initiative. Method: The KEEPS was a randomized, double-blinded, placebo-controlled trial to test the hypothesis that initiation of HT (oral conjugated equine estrogens [o-CEE] or transdermal 17β-estradiol [t-E 2 ]) in healthy, recently postmenopausal women ( n = 727) would slow the progression of atherosclerosis as measured by changes in carotid artery intima-media thickness (CIMT). Results: After 4 years, neither HT affected the rate of increase in CIMT. There was a trend for reduced accumulation of coronary artery calcium with o-CEE. There were no severe adverse effects, including venous thrombosis. Several ancillary studies demonstrated a positive effect on mood with o-CEE, and reduced hot flashes, improved sleep, and maintenance of bone mineral density with both treatments. Sexual function improved with t-E 2 . There were no significant effects of either treatment on cognition, breast pain, or skin wrinkling. Variants of genes associated with estrogen metabolism influenced the age of menopause and variability in effects of the HT on CIMT. Platelet activation associated with the development of white matter hyperintensities in the brain. Conclusions: KEEPS and its ancillary studies have supported the value and safety of the use of HT in recently postmenopausal women and provide a perspective for future research to optimize HT and health of postmenopausal women. The KEEPS continuation study continues to pursue these issues.
Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma
Trippa, Lorenzo , Gaffey, Sarah, Arrillaga‐Romany, Isabel , Lee, Eudocia Q. , Rinne, Mikael L. , Ahluwalia, Manmeet S. , Colman, Howard , Fell, Geoffrey, Lassman, Andrew B. , Meredith, David M. , Schiff, David , Welch, Mary , Wen, Patrick Y. , Galanis, Evanthia , Ahluwalia, Manmeet S , Alexander, Brian M. , Arrillaga‐Romany, Isabel , Colman, Howard , Fell, Geoffrey G. , Groot, John de , Drappatz, Jan , Nabors, Burt , Santagata, Sandro , Ligon, Keith L , Wen, Patrick Yung

Mayo Clinic

JCO Precision Oncology | March 27, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-13

10.1200/po.18.00071 | PMID 32914038 Get It

PURPOSE Adequately prioritizing the numerous therapies and biomarkers available in late-stage testing for patients with glioblastoma (GBM) requires an efficient clinical testing platform. We developed and implemented INSIGhT (Individualized Screening Trial of Innovative Glioblastoma Therapy) as a novel adaptive platform trial (APT) to develop precision medicine approaches in GBM. METHODS INSIGhT compares experimental arms with a common control of standard concurrent temozolomide and radiation therapy followed by adjuvant temozolomide. The primary end point is overall survival. Patients with newly diagnosed unmethylated GBM who are IDH R132H mutation negative and with genomic data available for biomarker grouping are eligible. At the initiation of INSIGhT, three experimental arms (neratinib, abemaciclib, and CC-115), each with a proposed genomic biomarker, are tested simultaneously. Initial randomization is equal across arms. As the trial progresses, randomization probabilities adapt on the basis of accumulating results using Bayesian estimation of the biomarker-specific probability of treatment impact on progression-free survival. Treatment arms may drop because of low probability of treatment impact on overall survival, and new arms may be added. Detailed information on the statistical model and randomization algorithm is provided to stimulate discussion on trial design choices more generally and provide an example for other investigators developing APTs. CONCLUSION INSIGhT (NCT02977780) is an ongoing novel biomarker-based, Bayesian APT for patients with newly diagnosed unmethylated GBM. Our goal is to dramatically shorten trial execution timelines while increasing scientific power of results and biomarker discovery using adaptive randomization. We anticipate that trial execution efficiency will also be improved by using the APT format, which allows for the collaborative addition of new experimental arms while retaining the overall trial structure.
Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: Primary results from the MARIANNE study.
Ellis, Paul Anthony, Barrios, Carlos H. , Eiermann, W., Im, Young‐Hyuck , Burris, Howard A. , Strasak, Alexander, Patre, Monika, Perez, Edith A. , Toi, Masakazu , Conte, PierFranco , Martín, Miguel , Pieńkowski, Tadeusz , Pivot, Xavier B.

Mayo Clinic

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 507-507

10.1200/jco.2015.33.15_suppl.507 Get It

Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy.
Margolese, Richard G., Julian, Thomas B. , Costantino, Joseph P., Vallow, Laura A., Albain, Kathy S. , Whitworth, Pat W. , Cianfrocca, Mary, Gross, Howard M., Soori, Gamini S. , Hopkins, Judith O. , Sturtz, Keren , Wozniak, Timothy F., Seay, Thomas E., Mamounas, Eleftherios P. , Cecchini, Reena S. , Ganz, Patricia A. , Brufsky, Adam , Fehrenbacher, Louis , Mamounas, Eleftherios P. , Wolmark, Norman

Mayo Clinic

Journal of Clinical Oncology | March 8, 2019 | Volume: 33 | Issue: 15_suppl | Pages: LBA500-LBA500

10.1200/jco.2015.33.15_suppl.lba500 Get It